Cardiovascular Disease

Global CVD Almanac

JACC released a special “almanac-style” issue highlighting the growing burden of cardiovascular disease worldwide. 

The Global Burden of Disease, Injuries, and Risk Factors study (GBD) is the world’s largest effort to track population cardiovascular health, recording global, regional, and national trends in mortality and disability since 1990. 

The analysis found that CVD remains the leading cause of death worldwide, responsible for 20M deaths and 400M disability-adjusted life-years lost in 2021. Here are the ACC’s main 2021 takeaways:

  • Ischemic heart disease was the leading cause of CV death, accounting for 9.4M deaths.
  • High systolic BP remained the leading modifiable risk factor for CV deaths, accounting for 10.8M. 
  • Dietary risks (like too few healthy and too many unhealthy foods) accounted for 6.6M CV deaths. 
  • CVD risk attributable to elevated systolic blood pressure was highest in Central Asia, Central Sub-Saharan Africa, and Eastern Europe.
  • CVD burden attributable to dietary risks was highest in Central Asia, Oceania, and Eastern Europe.
  • Central Asia had the highest age-standardized total CVD mortality at 517 deaths per 100k people, nearly 7 times higher than in Asia Pacific. 

On a brighter note, Australasia had the largest reduction (64.2%) in age-standardized CVD per 100k out of all other regions since 1990, driven by decreases in ischemic heart disease. 

The Takeaway

The ACC hopes to bring renewed attention to troubling trends related to the global CVD burden. The multi-year collaboration helps move the field forward by not only tracking CV risk and disease but also gauging whether interventions are actually effective. 

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square